Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 766

1.

High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.

Persson M, Brismar Wendel S, Ljungblad L, Johansson B, Weiderpass E, Andersson S.

Oncol Rep. 2012 Jul;28(1):346-52. doi: 10.3892/or.2012.1755. Epub 2012 Apr 3.

PMID:
22484610
2.

Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than Papanicolaou screening for women regardless of age.

Pierry D, Weiss G, Lack B, Chen V, Fusco J.

Arch Pathol Lab Med. 2012 Aug;136(8):956-60. doi: 10.5858/arpa.2011-0180-OA.

PMID:
22849745
3.

Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.

Cattani P, Zannoni GF, Ricci C, D'Onghia S, Trivellizzi IN, Di Franco A, Vellone VG, Durante M, Fadda G, Scambia G, Capelli G, De Vincenzo R.

J Clin Microbiol. 2009 Dec;47(12):3895-901. doi: 10.1128/JCM.01275-09. Epub 2009 Oct 14.

4.

Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.

Varnai AD, Bollmann M, Bankfalvi A, Speich N, Schmitt C, Griefingholt H, Kovács K, Klozoris C, Bollmann R.

Oncol Rep. 2008 Feb;19(2):457-65.

PMID:
18202795
5.

Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.

Perez Castro S, Iñarrea Fernández A, Lamas González MJ, Sarán Diez MT, Cid Lama A, Alvarez Martín MJ, Pato Mosquera M, López-Miragaya I, Estévez N, Torres Piñón J, Oña Navarro M.

J Med Virol. 2013 Jun;85(6):1063-8. doi: 10.1002/jmv.23544.

PMID:
23588733
6.

Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W.

BJOG. 2006 Nov;113(11):1303-7. Epub 2006 Sep 15.

7.

Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.

Keegan H, Mc Inerney J, Pilkington L, Grønn P, Silva I, Karlsen F, Bolger N, Logan C, Furuberg L, O'Leary J, Martin C.

J Virol Methods. 2009 Jan;155(1):61-6. doi: 10.1016/j.jviromet.2008.09.027. Epub 2008 Nov 13.

PMID:
18955086
8.

Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3.

Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Campo E, Pahisa J, Ordi J.

Gynecol Oncol. 2006 Nov;103(2):631-6. Epub 2006 Jun 14.

PMID:
16780934
9.

Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia.

Sathish N, Abraham P, Peedicayil A, Sridharan G, John S, Chandy G.

Mol Diagn. 2004;8(1):57-64.

PMID:
15230643
10.

Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.

Tropé A, Jonassen CM, Sjøborg KD, Nygård M, Dahl FA, Alfsen GC, Lie AK.

Gynecol Oncol. 2011 Nov;123(2):257-62. doi: 10.1016/j.ygyno.2011.07.032. Epub 2011 Aug 12.

PMID:
21839500
11.

HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.

Duvlis S, Popovska-Jankovic K, Arsova ZS, Memeti S, Popeska Z, Plaseska-Karanfilska D.

J Med Virol. 2015 Sep;87(9):1578-86. doi: 10.1002/jmv.24199. Epub 2015 Apr 16.

PMID:
25880030
12.

Use of hTERT and HPV E6/E7 mRNA RT-qPCR TaqMan assays in combination for diagnosing high-grade cervical lesions and malignant tumors.

Wang HY, Park S, Kim S, Lee D, Kim G, Kim Y, Park KH, Lee H.

Am J Clin Pathol. 2015 Mar;143(3):344-51. doi: 10.1309/AJCPF2XGZ2XIQYQX.

PMID:
25696792
13.

Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.

Lie AK, Kristensen G.

Expert Rev Mol Diagn. 2008 Jul;8(4):405-15. doi: 10.1586/14737159.8.4.405.

PMID:
18598223
14.

Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients.

Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, Rollo F, Ronchetti L, Muti P, Mariani L, Sindico S, Vocaturo G, Vocaturo A.

Cancer Causes Control. 2011 Jun;22(6):869-75. doi: 10.1007/s10552-011-9757-0. Epub 2011 Mar 19.

PMID:
21424209
15.

Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a.

Andersson S, Hansson B, Norman I, Gaberi V, Mints M, Hjerpe A, Karlsen F, Johansson B.

Int J Oncol. 2006 Sep;29(3):705-11.

PMID:
16865288
16.
17.

Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological Abnormalities.

Johansson H, Bjelkenkrantz K, Darlin L, Dilllner J, Forslund O.

PLoS One. 2015 Apr 20;10(4):e0124460. doi: 10.1371/journal.pone.0124460. eCollection 2015.

18.

Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction.

Sotlar K, Stubner A, Diemer D, Menton S, Menton M, Dietz K, Wallwiener D, Kandolf R, Bültmann B.

J Med Virol. 2004 Sep;74(1):107-16.

PMID:
15258976
19.

High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, Karlsen F, Morland E, Snijders PJ, Meijer CJ.

J Clin Microbiol. 2012 Jul;50(7):2390-6. doi: 10.1128/JCM.06587-11. Epub 2012 May 2.

20.

Clinical significance of signal pattern of high-risk human papillomavirus using a novel fluorescence in situ hybridization assay in cervical cytology.

Ho CM, Lee BH, Chang SF, Chien TY, Huang SH, Yan CC, Cheng WF.

Clin Microbiol Infect. 2011 Mar;17(3):386-94. doi: 10.1111/j.1469-0691.2010.03186.x.

Supplemental Content

Support Center